Edinburgh Postnatal Depression Scale

Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)

Retrieved on: 
Tuesday, April 23, 2024
Mental Health, Women, FDA, Baby, Maternity, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, American College, Regulation, PPD, Woman, Behavioral activation, Food, Cognitive behavioral therapy, BAT, Depression, DBT, Smartphone, Summer, ACOG, Therapy, Edinburgh Postnatal Depression Scale, Patient, MPH, Postpartum depression, Face, ITT, IPT, RCT, Dialectical behavior therapy, CBT, EPDS

Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.

Key Points: 
  • Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.
  • MamaLift Plus treats mild to moderate postpartum depression by improving a patient’s symptoms of depression.
  • MamaLift Plus delivers digital Cognitive Behavioral Therapy (CBT), Behavioral Activation Therapy (BAT), Interpersonal Therapy (IPT), and Dialectical Behavior Therapy (DBT) for postpartum depression.
  • The clearance of MamaLift Plus is based on results from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER).

Curio Digital Therapeutics: Pivotal Trial for Postpartum Depression Digital Therapeutic Meets Efficacy Endpoints

Retrieved on: 
Friday, October 6, 2023
Mental Health, Health, Consumer, Women, Baby, Maternity, Biotechnology, Diagnosis, Edinburgh Postnatal Depression Scale, Digital, Woman, Regulation, ITT, Summer, Patient, Pharmaceutical industry, EPDS

Curio Digital Therapeutics, Inc. (“Curio”), today announced positive data from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER) trial.

Key Points: 
  • Curio Digital Therapeutics, Inc. (“Curio”), today announced positive data from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER) trial.
  • SuMMER (NCT05958095), a study executed by HITLAB, a renowned healthcare innovation and research organization, is a randomized clinical trial of MamaLift Plus, a digital therapeutic for women experiencing perinatal mood disturbances.
  • Patients had baseline EPDS scores ≥ 13 but not exceeding 19, and a confirmed diagnosis of postpartum depression prior to enrollment.
  • The SuMMER trial met its primary endpoint, a ≥4-point improvement in Edinburgh Postnatal Depression Scale (EPDS) score.

Zuranolone for postpartum depression: Hope, hype or both?

Retrieved on: 
Thursday, August 31, 2023
Exercise, PPD, Human, Pregnancy, Depression, Awareness, Sertraline, Interpersonal psychotherapy, COVID-19, Mental health, Woman, Psychotherapy, Medicine, Research, Edinburgh Postnatal Depression Scale, Heart rate, Allopregnanolone, USD, Hormone, Mother, Dutch Association of Mental Health and Addiction Care, Blame, Zuranolone, Lactation, Sleep hygiene, Progesterone, FDA, Addiction, Safety, Pharmaceutical industry, Medical device, Nursing, Birth control, Health insurance

While mothers with postpartum depression have always faced barriers accessing the care they need, things have been particularly bad since the onset of the COVID-19 pandemic.

Key Points: 
  • While mothers with postpartum depression have always faced barriers accessing the care they need, things have been particularly bad since the onset of the COVID-19 pandemic.
  • However, the pandemic also coincided with a period of significant innovation in treatment that may increase access to and effectiveness of care.

Medications specifically for PPD

    • It represented the first of an entirely new class of medicines for postpardum depression (PPD), which target the steep decrease in hormones after delivery.
    • Brexanolone is a synthetic version of allopregnanolone, a naturally occurring substance made from progesterone, that helps the brain regulate stress.
    • Its approval in the U.S. was especially notable for two reasons: it was the first medicine approved specifically for the treatment of PPD, and it takes effect especially quickly — within 60 hours.
    • Early studies of zuranolone suggest PPD symptom improvement can be observed as early as three days after starting the treatment.

Behind the hype

    • If approved in Canada, it would also add to the array of effective treatments that already exist.
    • These include evidence-based talking therapies like cognitive behavioural therapy and interpersonal psychotherapy, which are first-line treatments for mild to moderate PPD.
    • Antidepressant medications like the selective serotonin re-uptake inhibitors (SSRIS, such as sertraline and escitalopram) are also widely available and usually recommended as second-line therapies for most individuals with PPD.
    • Only individuals with more severe depression that emerged between the third trimester of pregnancy and four weeks post-delivery could be enrolled.

PPD is still underdiagnosed

    • However, it is important in this case that we not lose sight of the fact that PPD is a vastly underdetected and undertreated problem for which safe and effective treatments already exist.
    • Research into treatments for PPD and the federal government’s actions in appointing a Minister of Mental Health and Addictions and prioritizing perinatal parents are also cause for genuine optimism.
    • While zuranolone is raising awareness about PPD, it’s important to highlight the need to develop national quality standards and Canadian-specific stepped-care models and care pathways.

Medela and Expectful Partner to Strengthen Support for New Mothers

Retrieved on: 
Thursday, May 5, 2022
Parent, Fertility, Journal of Perinatology, Meditation, Woman, GLOBE, Symphony, Pregnancy, Depression, Malena Josephsen, Milk, Mother, Patient, Clinical study design, NICU, Partnership, Hospital, Journal, Journal of Obstetric, Gynecologic, & Neonatal Nursing, Lactation, Edinburgh Postnatal Depression Scale, Health, Breast milk, IOS, Education, Android, Life, CEO, Research, Entrepreneurship, Consultant, Risk, Birth control, Sexually active life expectancy, Maternal–fetal medicine

Adjusted odds of a clinically significant Edinburgh Postnatal Depression Scale score of > 9 was 0.057 with frequent meditation.

Key Points: 
  • Adjusted odds of a clinically significant Edinburgh Postnatal Depression Scale score of > 9 was 0.057 with frequent meditation.
  • We are thrilled to connect breastfeeding families with our trusted breastfeeding education from Medela Family with the proven impact of Expectfuls mindfulness exercises.
  • Medela Family members will also have access to 30% off an annual membership to Expectfuls wellness app through November 25, 2022.
  • Through advancing research, observing natural behavior and listening to our customers, Medela turns science into care while nurturinghealth for generations.

Global e-Paper Display Market Report 2016-2018 & 2024 - Manufacturers Focus on Color Displays for Commercial Applications

Retrieved on: 
Tuesday, April 24, 2018
Edinburgh Postnatal Depression Scale, Digital signage, E-reader, Paper, Media technology, Psychology

Increasing Demand for EPDs in Electronic Shelf Tags, Mobiles and Digital Signage

Key Points: 

Increasing Demand for EPDs in Electronic Shelf Tags, Mobiles and Digital Signage
The Next Version of Kindle eReaders to be Waterproof, Offer Color and Integrate More Buttons